Senate User Fee Bill Heads To Mark-up Without Track-And-Trace
This article was originally published in The Pink Sheet Daily
Executive Summary
Manager’s amendment released in lead-up to committee mark-up still does not include drug tracking provisions, but will expand advisory committee recruiting and eliminate conflict of interest waivers using language in Rep. Burgess’ bill.
You may also be interested in...
User Fee Bills: After Mark-ups, How Will House And Senate Reconcile Differences?
House and Senate committee user fee bill mark-ups approaching, but drafts have differences in drug shortage, supply chain security and other proposed policy changes to reconcile.
Conflict Of Interest Rules Get Clean Sweep In House Draft User Fee Bill
Reforms merit one sentence, which would end waiver caps for conflicts of interest, but it is unclear whether it will solve the problems patient groups and others have with the advisory committee selection process.
Pain Prescriber Education Programs Need Better Coordination, GAO Says
FDA and other federal agencies could better coordinate their efforts to educate prescribers about prescription pain reliever abuse, the Government Accountability Office said.